Table 3. Factors associated with acceptance of ARV generics by patients.
| Refusal | Acceptance | p-value | ||
|---|---|---|---|---|
| N = 158 | N = 241 | |||
| N (%) | N (%) | |||
| Male sex | 99 (62.7) | 198 (82.2) | <0,001 | |
| Age, mean (sd) | 48.9 (10.8) | 49.2 (12.1) | 0.79 | |
| France native | 108 (69.7) | 192 (82.4) | 0,003 | |
| Living in the Ile-de-France region | 47 (29.8) | 57 (23.6) | 0,18 | |
| Educational high school diploma or higher | 26 (23.4) | 34 (24.8) | 0,80 | |
| In employment | 75 (48.7) | 136 (58.1) | 0,07 | |
| Social security coverage | 152 (96.8) | 233 (96.7) | 0,15 | |
| HIV duration ≥13ans | 78 (50.6) | 129 (55.4) | 0,36 | |
| Heterosexual transmission | 70 (48.6) | 71 (32.1) | 0,005 | |
| CDC stage | A | 73 (48.0) | 122 (54.5) | 0,03 |
| B | 28 (18.5) | 54 (24.1) | ||
| C | 51 (33.5 | 48 (21.4) | ||
| Treatment duration (years) | 11.3±6.8 | 10.6±7.1 | 0,29 | |
| Current CD4 count ≥500/mm3 | 101 (66.5) | 151 (64.0) | 0,62 | |
| CD4 nadir ≥200/mm3 | 143 (94.1) | 222 (94.1) | 0,99 | |
| HCV status | 18 (11.5) | 29 (12.0) | 0,19 | |
| HBV status | 8 (5.1) | 12 (5.0) | 0,86 | |
| Cardiovascular comorbidities | 22 (14.0) | 33 (13.7) | 0,75 | |
| All comorbidities | 62 (39.2) | 91 (37.8) | 0,77 | |
| Patient agreeing with the definition of a generic | 31 (19.8) | 224 (93.3) | <0,001 | |
| Patient having already received generics | 104 (70.8) | 217 (91.9) | <0,001 | |
| Patient foregoing third party payment | 20 (30.3) | 11 (13.6) | 0,03 | |
| Patient accepting generics per se | 59 (38.8) | 230 (96.6) | <0,001 | |